Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

29d ago

AVIR

PremiumPress Releases

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

2M ago

AVIR

PremiumPress Releases

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

4M ago

AVIR

PremiumPress Releases

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

4M ago

AVIR

PremiumPress Releases

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

5M ago

AVIR

PremiumPress Releases

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

6M ago

AVIR

PremiumPress Releases

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

6M ago

AVIR

More AVIR News >

AVIR News on the Web

2024-03-27

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Yahoo Finance

Neutral

2024-02-29

Atea Pharmaceuticals, Inc. Q4 2023 Earnings Call Transcript

Yahoo Finance

Neutral

2024-02-28

Atea Pharmaceuticals Inc Announces Q4 and Full Year 2023 Financial Results

Yahoo Finance

Neutral

2024-02-28

Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results

GuruFocus News

Bullish

2024-02-28

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Yahoo Finance

Neutral

2024-02-21

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

Yahoo Finance

Neutral

2024-02-15

Do Analysts Expect Atea Pharmaceuticals Inc (AVIR) Stock to Rise After It Is Up 22.51% in a Month?

Investors Observer

Neutral

2024-02-01

Is it Time to Dump Atea Pharmaceuticals Inc (AVIR) Stock After it Is Higher By 9.55% in a Week?

Investors Observer

Neutral

News Score - Last 7 Days

Not enough data to generate a sentiment score

Media Buzz

This Week0 articles

Weekly Average0 articles

News Sentiment

Currently, no data available

See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is AVIR’s Media Buzz Sentiment?

Currently, no data Available

What is AVIR’s weekly average amount of articles?

Currently, no data Available

What is AVIR’s News Sentiment?

Currently, no data Available

Healthcare Stocks that are Trending in the News

DAWNDay One Biopharmaceuticals

IMVTImmunovant

HSTMHealthStream

NBIXNeurocrine

RVVRevive Therapeutics

Showing the stocks with the most bullish news sentiment over the past week

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing